Lexeo Therapeutics (LXEO) Announces Proposed IPO

Lexeo Therapeutics (NASDAQ: LXEO) has filed for a proposed IPO.

From the filing: "We are a clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. By taking aim at the underlying genetic cause of the devastating diseases we target, we seek to create substantial positive impact and reduce the overwhelming burdens placed on people receiving treatment, their caregivers, and healthcare systems. Our current pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to our genetic medicine approach. "

J.P. Morgan, Leerink Partners, Stifel and RBC Capital Markets will serve as lead underwriters.

You May Also Be Interested In

• Stifel Reiterates Buy Rating on Lexeo Therapeutics (LXEO)
• Stifel on HubSpot Inc (HUBS) amid workforce cuts and restructuring: 'we expect pricing will remain a key focus around the story'
• ADARx IPO raises $602.5M after underwriters exercise full option